iGo, Inc. (Nasdaq:IGOI) announced that the Company will hold a conference call to discuss financial results for the first quarter of 2011 and provide a general business update on Thursday, May 5, 2011 at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time.
iGo, Inc. and its subsidiaries engage in the design, development, manufacture, and distribution of power products for high-power and low-power mobile electronic devices.
Orofino Gold Corp. (ORFG)
Comprising of a set of outstanding qualities, gold is well liked amongst all the other metals. It has the capability of maintaining its appearance, conducting electricity and is safe to use. Along with this, it is easily bended, melted, and given any shape that is preferred. All humans have a special liking for this metal, not just for its properties, but also for its look.
Orofino Gold Corp. is a Colombia based gold producer founded as a private company in 2009 by former executives with over 50 cumulative years in mining exploration, finance, and development expertise.
Out of the many fields of electronics gold is commonly used in plating connection between connectors, relays, and switches. Electronic appliances that require large amounts of electricity have electrical wiring made out of gold. Undoubtedly, gold is used heavily in the field of electronics, and holds an important position.
Orofino Gold Corp. has several Gold development properties in Colombia, a current hot spot of gold production in the world markets.
There are electronic gadgets, which need very low level of voltage, and current, however attrition can cause trouble. This trouble is solved away when gold is used, since it can bear being worn off. Being a good conductor of heat, ability of carrying currents easily and fighting erosion are the features, which make gold important for electronics. Gold is also used heavily in linking wires, soldered joints, and linking strips.
Orofino’s corporate objective is to continue to build shareholder value through the exploration and development of Senderos de Oro and additional accretive acquisitions, capitalizing on the extensive experience and relationships that management has developed over the past 25 years.
Orofino Gold Corp. recently announced results from random chip samples within their Culo Alzado mining area, on the north margin of Senderos de Oro, in Colombia that indicate high grades. A newly recognized gold and silver zone has been discovered in this mining area and the current exploration program will be escalated as recommended by the company’s Qualified Person. A complete listing of Acme Analytical Laboratories reports is available on the Company’s website at www.orofinogoldcorp.com.
For more information about Orofino Gold Corp. www.orofinogoldcorp.com
Power3 Medical Products, Inc (PWRME)
Women in the United States have a one-in-seven chance of developing breast cancer at some point in their lives. An extensive movement is pressing for more research on the causes of breast cancer, particularly the effect of the environment, so that preventive measures and better treatment can be developed. Certain chemicals are associated with cancer in lab animals and/or humans.
Power3 Medical Products, Inc. is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig’s disease).
Diets high in animal fat may increase the amount of fat-soluble toxins, such as dioxin, and some pesticides in your body. Over time, these compounds may trigger breast cancer by disrupting normal cell-regulation processes in sensitive breast tissue. Although women workers with high exposure to dioxin have significantly high rates of breast cancer, recent studies of endocrine disruptors and breast cancer were inconclusive. As a result, women face difficulties in assured safety at work or in avoiding hazardous chemicals that they may not even know are present in their environment. It is more important than ever for women to insist that government and industrial interests accept the responsibility for their contribution to environmental and workplace hazards that may cause cancer.
Power3 applies proprietary methodologies to discover and identify protein biomarkers associated with diseases. Through these processes, Power3 has developed a portfolio of product NuroPro�, a proteomic blood serum test for the detection of neurodegenerative diseases, including Alzheimer’s, Parkinson’s, and ALS diseases, for which it is currently engaged in Phase II clinical trials. These tests are designed to analyze an individual’s proteins to detect the presence of disease, a patient’s disease progression, a patient’s response to a particular drug, and the mechanisms of disease present in the patient for optimal targeted therapy.
BC-SeraPro� is a proteomic test for the diagnosis of breast cancer. This test is designed to measure the quantitative expression level of 22 protein biomarkers in the serum that differentiate between breast cancer patients and control subjects. The level of the biomarkers from the patient’s serum sample is compared to the Power3 Medical Products’ patient database. Statistical analysis by linear discriminant function will analyze the biomarker levels of the patient sample and assign a probability score for the diagnosis of the patient sample. Probability score is ranged from 0.0 to 1.0. Results of the BC-SeraPro� test should not be considered a standalone diagnosis nor a guarantee and is intended to be used in conjunction with mammography and other accepted modalities.
For more information about Power3 Medical Products, Inc. please visit http://www.power3medical.com
Legacy Reserves Lp (Nasdaq:LGCY) announced it will report its first quarter 2011 results on Wednesday, May 4, 2011, following the close of NASDAQ trading. A teleconference and web cast will be held on Thursday, May 5, 2011, beginning at 9:00 a.m. (Central Time). Those wishing to participate in the conference call should dial 877-266-0479. A replay of the call will be available through Monday, May 9, 2011, by dialing 706-645-9291 or 800-642-1687 and entering replay code 63833426.
Legacy Reserves LP, an independent oil and natural gas limited partnership, engages in the acquisition and development of oil and natural gas properties, primarily located in the Permian Basin, Mid-continent, and Rocky Mountain regions of the United States.
Harvard Bioscience Inc. (Nasdaq:HBIO) reported unaudited financial highlights for the first quarter ended March 31, 2011. Revenues for the three months ended March 31, 2011 were $26.3 million, which were flat with the first quarter of 2010. Net income, as measured under U.S. generally accepted accounting principles (”GAAP”), was $1.7 million, or $0.06 per diluted share for the three months ended March 31, 2011 compared to $2.2 million, or $0.07 per diluted share, for the same period in 2010. Non-GAAP adjusted net income was $2.1 million, or $0.07 per diluted share, for the first quarter of 2011 compared to $2.7 million, or $0.09 per diluted share, for the first quarter of 2010. Non-GAAP adjusted earnings per share for our core Life Science Research Tools business (”LSRT”) for the first quarter of 2011 was $0.08 and for our Regenerative Medicine business (”RMD”) was a $0.01 per diluted share loss. These results were in line with our previously-provided first quarter 2011 earnings guidance, given on February 25, 2011, of $0.08-$0.09 for LSRT and a loss of $0.01-$0.015 for RMD.
Harvard Bioscience, Inc. develops, manufactures, and markets apparatus and scientific instruments used in life science research in pharmaceutical and biotechnology companies, universities, and government laboratories in the United States and internationally.